Abhishek Jha
@ajelucidata.bsky.social
Co-Founder & CEO, Elucidata | Fast Company's Most Innovative Biotech Companies 2024 | Data-centric Biological Discovery | AI & ML Innovation
A three‑hour “boring” deep dive on a hospital software company shouldn’t be the thing that shakes your worldview, but this one did for me. Epic went from “annoying EMR vendor” in my head to a quiet masterclass in vertical software, data moats, and playing the long game in a life‑or‑death domain.
January 28, 2026 at 4:40 AM
A three‑hour “boring” deep dive on a hospital software company shouldn’t be the thing that shakes your worldview, but this one did for me. Epic went from “annoying EMR vendor” in my head to a quiet masterclass in vertical software, data moats, and playing the long game in a life‑or‑death domain.
AI is great at pattern matching. In drug discovery, that’s not enough.
Joined the @DataStorage team to talk about:
Why pattern‑matching AI breaks in messy biology
OOD problems as the real opportunity
Data‑centric vs model‑centric AI
Infra, costs, and deploying safely in regulated environments
Joined the @DataStorage team to talk about:
Why pattern‑matching AI breaks in messy biology
OOD problems as the real opportunity
Data‑centric vs model‑centric AI
Infra, costs, and deploying safely in regulated environments
January 14, 2026 at 11:01 AM
AI is great at pattern matching. In drug discovery, that’s not enough.
Joined the @DataStorage team to talk about:
Why pattern‑matching AI breaks in messy biology
OOD problems as the real opportunity
Data‑centric vs model‑centric AI
Infra, costs, and deploying safely in regulated environments
Joined the @DataStorage team to talk about:
Why pattern‑matching AI breaks in messy biology
OOD problems as the real opportunity
Data‑centric vs model‑centric AI
Infra, costs, and deploying safely in regulated environments
Not a victory lap. Just an honest check-in on what moved, what hurt, and what’s worth doubling down on next year.
This newsletter is a simple pass through my own highlights, lowlights, and funlights from 2025, and a small prompt to choose better inputs, not just chase better outcomes, in 2026.
This newsletter is a simple pass through my own highlights, lowlights, and funlights from 2025, and a small prompt to choose better inputs, not just chase better outcomes, in 2026.
December 30, 2025 at 7:47 AM
Not a victory lap. Just an honest check-in on what moved, what hurt, and what’s worth doubling down on next year.
This newsletter is a simple pass through my own highlights, lowlights, and funlights from 2025, and a small prompt to choose better inputs, not just chase better outcomes, in 2026.
This newsletter is a simple pass through my own highlights, lowlights, and funlights from 2025, and a small prompt to choose better inputs, not just chase better outcomes, in 2026.
Every biopharma leader agrees: “Pre-competitive data sharing is essential.”
Yet when it’s time to act, no one moves first. Here's what I think about it- 👇
Yet when it’s time to act, no one moves first. Here's what I think about it- 👇
November 8, 2025 at 11:38 AM
Every biopharma leader agrees: “Pre-competitive data sharing is essential.”
Yet when it’s time to act, no one moves first. Here's what I think about it- 👇
Yet when it’s time to act, no one moves first. Here's what I think about it- 👇
Some people think “data-centric AI” means having more data.
It doesn’t. It means.....
..Having fewer regrets!
#CleanData #SmarterAI #DataCentricAI
It doesn’t. It means.....
..Having fewer regrets!
#CleanData #SmarterAI #DataCentricAI
November 7, 2025 at 3:59 PM
Some people think “data-centric AI” means having more data.
It doesn’t. It means.....
..Having fewer regrets!
#CleanData #SmarterAI #DataCentricAI
It doesn’t. It means.....
..Having fewer regrets!
#CleanData #SmarterAI #DataCentricAI
Most founders over-index on product. GTM success = knowing your ACV, product complexity, and who decides (champion or committee).
“AI” isn’t a GTM differentiator, clear value is.
What GTM mistake slowed you down the most?
#startups #AI #healthtech
“AI” isn’t a GTM differentiator, clear value is.
What GTM mistake slowed you down the most?
#startups #AI #healthtech
November 4, 2025 at 6:33 AM
Most founders over-index on product. GTM success = knowing your ACV, product complexity, and who decides (champion or committee).
“AI” isn’t a GTM differentiator, clear value is.
What GTM mistake slowed you down the most?
#startups #AI #healthtech
“AI” isn’t a GTM differentiator, clear value is.
What GTM mistake slowed you down the most?
#startups #AI #healthtech
Gearing up for 𝗗𝗮𝘁𝗮𝗙𝗔𝗜𝗥 2025 in Boston.
7 years in, we ask the hard questions:
• Can AI & LLMs actually speed drug discovery?
• What bold bets will reset pharma?
• How do we move from pilots → production?
Oct 23, let’s dig in.
#LifeSciences #AIinBiopharma
7 years in, we ask the hard questions:
• Can AI & LLMs actually speed drug discovery?
• What bold bets will reset pharma?
• How do we move from pilots → production?
Oct 23, let’s dig in.
#LifeSciences #AIinBiopharma
October 16, 2025 at 8:13 PM
Gearing up for 𝗗𝗮𝘁𝗮𝗙𝗔𝗜𝗥 2025 in Boston.
7 years in, we ask the hard questions:
• Can AI & LLMs actually speed drug discovery?
• What bold bets will reset pharma?
• How do we move from pilots → production?
Oct 23, let’s dig in.
#LifeSciences #AIinBiopharma
7 years in, we ask the hard questions:
• Can AI & LLMs actually speed drug discovery?
• What bold bets will reset pharma?
• How do we move from pilots → production?
Oct 23, let’s dig in.
#LifeSciences #AIinBiopharma
The "we'll build our own AI" era just ended.
Takeda ↔ Nabla Bio: Renewed
Sanofi: New AI deal
Salt AI: $10M raised
Shuttle acquires Molecule. ai
The smart money figured out: AI isn't a feature you build—it's an ecosystem you join.
Takeda ↔ Nabla Bio: Renewed
Sanofi: New AI deal
Salt AI: $10M raised
Shuttle acquires Molecule. ai
The smart money figured out: AI isn't a feature you build—it's an ecosystem you join.
October 15, 2025 at 9:23 AM
The "we'll build our own AI" era just ended.
Takeda ↔ Nabla Bio: Renewed
Sanofi: New AI deal
Salt AI: $10M raised
Shuttle acquires Molecule. ai
The smart money figured out: AI isn't a feature you build—it's an ecosystem you join.
Takeda ↔ Nabla Bio: Renewed
Sanofi: New AI deal
Salt AI: $10M raised
Shuttle acquires Molecule. ai
The smart money figured out: AI isn't a feature you build—it's an ecosystem you join.
Earlier last week in #Philadelphia, we hosted a small group dinner during #BioTechX USA 2025.
It felt great to sit down with heads of R&D, data, and operations from #pharma, #biotech, and #diagnostics hearing directly what they care about and what still trips teams up.
It felt great to sit down with heads of R&D, data, and operations from #pharma, #biotech, and #diagnostics hearing directly what they care about and what still trips teams up.
September 23, 2025 at 10:30 AM
Earlier last week in #Philadelphia, we hosted a small group dinner during #BioTechX USA 2025.
It felt great to sit down with heads of R&D, data, and operations from #pharma, #biotech, and #diagnostics hearing directly what they care about and what still trips teams up.
It felt great to sit down with heads of R&D, data, and operations from #pharma, #biotech, and #diagnostics hearing directly what they care about and what still trips teams up.
Clinical & real-world datasets can unlock breakthroughs in #drugdevelopment & #precisionmedicine - but patient data is fragmented across labs, imaging, omics & outcomes.
Join us to see how we unify it into a #KnowledgeGraph!
👉 bit.ly/kg-webinar_p...
Join us to see how we unify it into a #KnowledgeGraph!
👉 bit.ly/kg-webinar_p...
September 12, 2025 at 6:01 PM
Clinical & real-world datasets can unlock breakthroughs in #drugdevelopment & #precisionmedicine - but patient data is fragmented across labs, imaging, omics & outcomes.
Join us to see how we unify it into a #KnowledgeGraph!
👉 bit.ly/kg-webinar_p...
Join us to see how we unify it into a #KnowledgeGraph!
👉 bit.ly/kg-webinar_p...
Data scientist: “Do we need provenance tracking?”
"Yes. Because blind trust is not FDA-compliant."
"Yes. Because blind trust is not FDA-compliant."
September 4, 2025 at 10:21 AM
Data scientist: “Do we need provenance tracking?”
"Yes. Because blind trust is not FDA-compliant."
"Yes. Because blind trust is not FDA-compliant."
One of my personal goals has always been to give back time to scientists - so they can focus on what they do best: bringing life-changing therapies to patients.
This goal didn’t come from a business plan. It came from a conversation that’s stayed with me for years.
1/4
This goal didn’t come from a business plan. It came from a conversation that’s stayed with me for years.
1/4
September 1, 2025 at 12:04 PM
One of my personal goals has always been to give back time to scientists - so they can focus on what they do best: bringing life-changing therapies to patients.
This goal didn’t come from a business plan. It came from a conversation that’s stayed with me for years.
1/4
This goal didn’t come from a business plan. It came from a conversation that’s stayed with me for years.
1/4
One of my biggest goals has always been simple: give scientists back time. Because behind every therapy, every discovery, is someone fighting not just biology, but time.
And sometimes an extra hour can change everything.
#personalstory #CEO
And sometimes an extra hour can change everything.
#personalstory #CEO
August 31, 2025 at 5:40 PM
One of my biggest goals has always been simple: give scientists back time. Because behind every therapy, every discovery, is someone fighting not just biology, but time.
And sometimes an extra hour can change everything.
#personalstory #CEO
And sometimes an extra hour can change everything.
#personalstory #CEO
“A team of PhD-level experts in your pocket.”
That’s how Sam Altman pitched #GPT5
We stress-tested that claim on a real #genomics problem - the kind scientists wrestle with daily in code and data.
Did it live up to the hype?
👉 elucidata.io/blog/gpt5-ph...
#PhD #GPT5
That’s how Sam Altman pitched #GPT5
We stress-tested that claim on a real #genomics problem - the kind scientists wrestle with daily in code and data.
Did it live up to the hype?
👉 elucidata.io/blog/gpt5-ph...
#PhD #GPT5
August 29, 2025 at 5:39 PM
“A team of PhD-level experts in your pocket.”
That’s how Sam Altman pitched #GPT5
We stress-tested that claim on a real #genomics problem - the kind scientists wrestle with daily in code and data.
Did it live up to the hype?
👉 elucidata.io/blog/gpt5-ph...
#PhD #GPT5
That’s how Sam Altman pitched #GPT5
We stress-tested that claim on a real #genomics problem - the kind scientists wrestle with daily in code and data.
Did it live up to the hype?
👉 elucidata.io/blog/gpt5-ph...
#PhD #GPT5
Delays in PK/PD data retrieval from trial PDFs can stall decisions by up to 2 weeks, push trial start dates back by months & even give competitors early access to trial sites.
Time to rethink data accessibility in clinical research.
👉 bit.ly/webinar-xtract
#ClinicalTrials #Discovery #AI
Time to rethink data accessibility in clinical research.
👉 bit.ly/webinar-xtract
#ClinicalTrials #Discovery #AI
August 25, 2025 at 6:04 AM
Delays in PK/PD data retrieval from trial PDFs can stall decisions by up to 2 weeks, push trial start dates back by months & even give competitors early access to trial sites.
Time to rethink data accessibility in clinical research.
👉 bit.ly/webinar-xtract
#ClinicalTrials #Discovery #AI
Time to rethink data accessibility in clinical research.
👉 bit.ly/webinar-xtract
#ClinicalTrials #Discovery #AI
No one announces a “data quality failure.”
It shows up as delays, poor model performance, regulatory headaches, and slipping timelines.
We’re great at collecting data, less so at making it usable.
In science, shaky data is a risk, not just tech debt.
#Biomedicaldata #AI
It shows up as delays, poor model performance, regulatory headaches, and slipping timelines.
We’re great at collecting data, less so at making it usable.
In science, shaky data is a risk, not just tech debt.
#Biomedicaldata #AI
August 7, 2025 at 6:06 PM
No one announces a “data quality failure.”
It shows up as delays, poor model performance, regulatory headaches, and slipping timelines.
We’re great at collecting data, less so at making it usable.
In science, shaky data is a risk, not just tech debt.
#Biomedicaldata #AI
It shows up as delays, poor model performance, regulatory headaches, and slipping timelines.
We’re great at collecting data, less so at making it usable.
In science, shaky data is a risk, not just tech debt.
#Biomedicaldata #AI
I recently spoke to a biotech team scaling translational research. They have it all - EHRs, omics, imaging, trial data.
On paper: perfect. In reality: chaos.
Mismatched timestamps, missing metadata, systems that don’t talk.
The data exists. But it’s not usable.
#dataquality #AI
On paper: perfect. In reality: chaos.
Mismatched timestamps, missing metadata, systems that don’t talk.
The data exists. But it’s not usable.
#dataquality #AI
August 6, 2025 at 6:53 PM
I recently spoke to a biotech team scaling translational research. They have it all - EHRs, omics, imaging, trial data.
On paper: perfect. In reality: chaos.
Mismatched timestamps, missing metadata, systems that don’t talk.
The data exists. But it’s not usable.
#dataquality #AI
On paper: perfect. In reality: chaos.
Mismatched timestamps, missing metadata, systems that don’t talk.
The data exists. But it’s not usable.
#dataquality #AI
1 day left. Have you registered yet?
🔗 Register: bit.ly/kg_webinar
#webinar #AI #knowledgegraph #research
🔗 Register: bit.ly/kg_webinar
#webinar #AI #knowledgegraph #research
August 4, 2025 at 7:54 PM
1 day left. Have you registered yet?
🔗 Register: bit.ly/kg_webinar
#webinar #AI #knowledgegraph #research
🔗 Register: bit.ly/kg_webinar
#webinar #AI #knowledgegraph #research
🔗 Register: bit.ly/kg_webinar
Polly KG introduces a programmable knowledge layer purpose-built for life sciences R&D. It supports natural language queries, cross-species reasoning, and domain-specific scoring within secure, enterprise environments.
Polly KG introduces a programmable knowledge layer purpose-built for life sciences R&D. It supports natural language queries, cross-species reasoning, and domain-specific scoring within secure, enterprise environments.
July 31, 2025 at 6:51 PM
🔗 Register: bit.ly/kg_webinar
Polly KG introduces a programmable knowledge layer purpose-built for life sciences R&D. It supports natural language queries, cross-species reasoning, and domain-specific scoring within secure, enterprise environments.
Polly KG introduces a programmable knowledge layer purpose-built for life sciences R&D. It supports natural language queries, cross-species reasoning, and domain-specific scoring within secure, enterprise environments.
After my recent post, it’s clear: the pain around knowledge graphs in biopharma is real.
Disconnected schemas. No context. Engineers overloaded for basic queries.
We’ve been there. We’ve felt that too. And it’s exactly why we built Polly KG.
Disconnected schemas. No context. Engineers overloaded for basic queries.
We’ve been there. We’ve felt that too. And it’s exactly why we built Polly KG.
July 28, 2025 at 7:37 PM
After my recent post, it’s clear: the pain around knowledge graphs in biopharma is real.
Disconnected schemas. No context. Engineers overloaded for basic queries.
We’ve been there. We’ve felt that too. And it’s exactly why we built Polly KG.
Disconnected schemas. No context. Engineers overloaded for basic queries.
We’ve been there. We’ve felt that too. And it’s exactly why we built Polly KG.
When we built Polly KG, we weren’t trying to make just another #knowledgegraph.
We built it to move past rigid schemas, surface NLP, and endless engineering loops - so scientists could just ask and answer questions that matter.
Join us on Aug 5 - bit.ly/kg_webinar
#webinar #AI #bioinformatics
We built it to move past rigid schemas, surface NLP, and endless engineering loops - so scientists could just ask and answer questions that matter.
Join us on Aug 5 - bit.ly/kg_webinar
#webinar #AI #bioinformatics
July 25, 2025 at 6:41 PM
When we built Polly KG, we weren’t trying to make just another #knowledgegraph.
We built it to move past rigid schemas, surface NLP, and endless engineering loops - so scientists could just ask and answer questions that matter.
Join us on Aug 5 - bit.ly/kg_webinar
#webinar #AI #bioinformatics
We built it to move past rigid schemas, surface NLP, and endless engineering loops - so scientists could just ask and answer questions that matter.
Join us on Aug 5 - bit.ly/kg_webinar
#webinar #AI #bioinformatics
Reposted by Abhishek Jha
We recently ran a closed Agentic AI workshop with biopharma R&D leaders - every seat filled. Now we’re opening it up virtually.
Join us to build AI agents that actually work with biomedical data.
Request your invite: bit.ly/AgenticAIwor...
#AI #biopharma #clinical #workshop
Join us to build AI agents that actually work with biomedical data.
Request your invite: bit.ly/AgenticAIwor...
#AI #biopharma #clinical #workshop
July 17, 2025 at 8:15 PM
We recently ran a closed Agentic AI workshop with biopharma R&D leaders - every seat filled. Now we’re opening it up virtually.
Join us to build AI agents that actually work with biomedical data.
Request your invite: bit.ly/AgenticAIwor...
#AI #biopharma #clinical #workshop
Join us to build AI agents that actually work with biomedical data.
Request your invite: bit.ly/AgenticAIwor...
#AI #biopharma #clinical #workshop
Have you registered yourself yet? If not, you should do it soon.
👉 bit.ly/AgenticAIwor...
#AI #data #workshops #AgenticAI
👉 bit.ly/AgenticAIwor...
#AI #data #workshops #AgenticAI
We recently ran a closed Agentic AI workshop with biopharma R&D leaders - every seat filled. Now we’re opening it up virtually.
Join us to build AI agents that actually work with biomedical data.
Request your invite: bit.ly/AgenticAIwor...
#AI #biopharma #clinical #workshop
Join us to build AI agents that actually work with biomedical data.
Request your invite: bit.ly/AgenticAIwor...
#AI #biopharma #clinical #workshop
July 20, 2025 at 6:24 AM
Have you registered yourself yet? If not, you should do it soon.
👉 bit.ly/AgenticAIwor...
#AI #data #workshops #AgenticAI
👉 bit.ly/AgenticAIwor...
#AI #data #workshops #AgenticAI
Still thinking about the energy at the Festival of Genomics & Biodata in Boston!
Every R&D conversation circled back to AI in cohorting, multi-omics, and the need for better, context-rich data.
Thanks to all who joined our session or stopped by.
Snapshots from the talk👇
Every R&D conversation circled back to AI in cohorting, multi-omics, and the need for better, context-rich data.
Thanks to all who joined our session or stopped by.
Snapshots from the talk👇
July 18, 2025 at 7:46 PM
Still thinking about the energy at the Festival of Genomics & Biodata in Boston!
Every R&D conversation circled back to AI in cohorting, multi-omics, and the need for better, context-rich data.
Thanks to all who joined our session or stopped by.
Snapshots from the talk👇
Every R&D conversation circled back to AI in cohorting, multi-omics, and the need for better, context-rich data.
Thanks to all who joined our session or stopped by.
Snapshots from the talk👇
We recently ran a closed Agentic AI workshop with biopharma R&D leaders - every seat filled. Now we’re opening it up virtually.
Join us to build AI agents that actually work with biomedical data.
Request your invite: bit.ly/AgenticAIwor...
#AI #biopharma #clinical #workshop
Join us to build AI agents that actually work with biomedical data.
Request your invite: bit.ly/AgenticAIwor...
#AI #biopharma #clinical #workshop
July 17, 2025 at 8:15 PM
We recently ran a closed Agentic AI workshop with biopharma R&D leaders - every seat filled. Now we’re opening it up virtually.
Join us to build AI agents that actually work with biomedical data.
Request your invite: bit.ly/AgenticAIwor...
#AI #biopharma #clinical #workshop
Join us to build AI agents that actually work with biomedical data.
Request your invite: bit.ly/AgenticAIwor...
#AI #biopharma #clinical #workshop